



ABC NEWSLETTER

CURRENT EVENTS AND TRENDS IN BLOOD SERVICES

Visit ABC's Web site at: www.americasblood.org

2022 #30

August 26, 2022

INSIDE:

WORD IN WASHINGTON	2
RESEARCH IN BRIEF	3
ABC Launches Meetings Survey	4
Elks Lodges Partner with ABC to Host Blood Drives throughout August	4
ABC Partners to Attempt World Record Blood Drive	4
MEMBER NEWS	5
PEOPLE	5
GLOBAL NEWS	7
COMPANY NEWS	7
CALENDAR	8
EQUIPMENT AVAILABLE	9
POSITIONS	9

New Member Programs Coming Soon

This week, Americas' Blood Centers (ABC) officially announced the launch of four new initiatives for member blood centers. The programs are focused on public awareness and workforce recruitment. The programs include a:

- Blood Drive Sponsor Recognition Program – this national program will recognize blood drive sponsors in each state that demonstrate a high level of support to their local blood supply;
- Blood Center Internship Program – this program expands on ABC's and ADRP's recently [launched](#) high school education program and HOSA [partnership](#) to continue to engage students in both blood donation and blood center careers;
- Blood Advocacy Week – will occur each April and feature a full week of national activities that engage Congress, federal agencies and the Executive Branch, state governments, and the media. Each day will feature the various segments that support a robust blood supply — donors, sponsors, and patients; and
- Blood Center Career Video – a new video centered around the various career opportunities and benefits of working at a community blood center.

Additional details including slides describing the programs more in-depth are available to ABC members in MCN 22-074. Contact [us](#) to receive a copy of the MCN.

(Source: MCN 22-074, 8/26/22) 💧

CMS Extends Comment Period for CLIA Fees Proposed Rule

The Centers for Medicare and Medicaid Services (CMS) has [extended](#) the comment period to September 26th for a proposed rule titled “Clinical Laboratory Improvement Amendments of 1988 (CLIA) Fees; Histocompatibility, Personnel, and Alternative Sanctions for Certificate of Waiver Laboratories.” The rule specifically proposes:

- CLIA Fee increases (20 percent across the board effective immediately after the final rule is published) to provide sustainable funding for the CLIA program;

(continued on page 2)

CMS Extends Comment Period (continued from page 1)

- additional fees for follow-up surveys, substantiated complaint surveys, and revised certificates; a nominal increase in Certificate of Waiver fees to distribute the administrative costs of test complexity determination for waived test systems;
- an amendment of the histocompatibility and personnel regulations to address obsolete regulations and account for technological advances (per America's Blood Center's (ABC) previous [comments](#) to CMS in 2018); and
- amending the provisions governing alternative sanctions (including civil money penalties, a directed plan of correction and onsite monitoring) for Certificate of Waiver laboratories.

ABC and more than 20 organizations previously signed-on to a letter on August 3rd requesting an [extension](#) of the comment period. Please contact ABC Director of Regulatory Affairs [Jill Mastin](#) with any questions or comments.

(Sources: CMS Proposed Rule [Extension](#), 8/25/22; [Sign-on Letter](#), 8/3/22) 💧

WORD IN WASHINGTON

Anthony Fauci, MD has [announced](#) that he will be “stepping down from the positions of Director of the National Institute of Allergy and Infectious Diseases (NIAID) and Chief of the NIAID Laboratory of Immunoregulation, as well as the position of Chief Medical Advisor to President Biden” in December 2022. In a statement, Dr. Fauci expressed gratitude for his nearly 40 years of service. “Over the past 38 years as NIAID Director, I have had the enormous privilege of serving under and advising seven Presidents of the United States, beginning with President Ronald Reagan, on newly emerging and re-emerging infectious disease threats including HIV/AIDS, West Nile virus, the anthrax attacks, pandemic influenza, various bird influenza threats, Ebola and Zika, among others, and, of course, most recently the COVID-19 pandemic...Over the coming months, I will continue to put my full effort, passion, and commitment into my current responsibilities, as well as help prepare the Institute for a leadership transition. [The] National Institutes of Health is served by some of the most talented scientists in the world, and I have no doubt that I am leaving this work in very capable hands.”

(Source: NIAID [Statement](#), 8/22/22)

The 2022 Center for Biologics Evaluation and Research (CBER) Science [Symposium](#) will take place virtually September 20th-22nd. According to an agency announcement, [registration](#) is open as the symposium will include presentations on:

- advanced manufacturing and analytics;
- advances in computational science supporting biologics' evaluation;
- biomarker discovery;
- immune responses to vaccination;
- genome therapy including gene editing; and
- emerging and re-emerging diseases.

An [agenda](#) for the symposium has also been published.

(Source: CBER [Announcement](#), 8/19/22) 💧



RESEARCH IN BRIEF

Prehospital plasma is associated with survival in patients transferred from the scene of injury. A study published in *Surgery* was “a secondary analysis of data from a recently completed prehospital plasma clinical trial [PAMPer] to determine if transfer origin from the scene of injury (SCENE) or from a referral hospital (REF) alters the beneficial outcome effects of prehospital plasma in patients at risk of hemorrhagic shock.” The authors explained that “[p]atients with blunt or penetrating injuries were eligible for enrollment... [P]atients received two units of either group AB or group A with a low anti-B antibody titer (<1:100) thawed plasma or standard prehospital air medical care [crystalloid-based resuscitation]... The primary outcome for the current analysis was 30-day mortality... The secondary outcomes of interest included 24-hour mortality.” The study included “390 SCENE and 111 REF” patients. The investigators noted that “there was a significant 24-hour survival benefit in SCENE patients who received plasma compared to those who received standard of care ($P=.005$) but not in transfer patients ($P=.37$)... Similarly, there was a significant 30-day survival benefit in SCENE group patients who received plasma compared to those who received standard of care ($P=.002$) but not in transfer patients ($P=.36$).” According to the authors, the study models “demonstrated that prehospital plasma treatment was associated with a 43 percent reduction in risk of 24-hour mortality and a 41 percent reduction in risk of 30-day mortality in SCENE group... There was no significant mortality benefit associated with prehospital plasma found in REF group patients (24-hour HR 1.05, $P=.93$; 30-day HR 1.03, $P=.95$).” The study concluded that “prehospital plasma is significantly associated with higher survival in trauma patients at risk for hemorrhagic shock who arrive from the scene of injury, although no significant association is demonstrated for those who are transferred from a referral emergency department... The underlying reasons for these disparate outcome findings remain obscure, but these outcome differences may be important when planning for future prehospital interventional trials, particularly when a plasma based intervention is used.”

Citation: Lewis, R.E., Muluk, S.L., Reitz, K.M., *et al.* [Prehospital plasma is associated with survival principally in patients transferred from the scene of injury: A secondary analysis of the PAMPer trial.](#) *Surgery*. 2022.

Contributed by Richard Gammon, MD, Medical Director at OneBlood 💧



The *ABC Newsletter* (ISSN #1092-0412) is published by America’s Blood Centers® and distributed by e-mail. Contents and views expressed are not official statements of ABC or its Board of Directors. Copyright 2022 by America’s Blood Centers. Reproduction of the *ABC Newsletter* is forbidden unless permission is granted by the publisher. (ABC members need not obtain prior permission if proper credit is given.)

ABC advocates for and advances policies that promote the role of independent blood centers in providing life-saving blood products and recognize the continuous need for a safe and robust blood supply. ABC exists to advocate for laws and regulations recognizing the essential role that independent blood centers play in the health care system; promote partnerships, policies and programs that increase awareness about the need for blood donation; and serve as a thought-leader in the advancement of evidence-based medical and scientific solutions related to health and safety.

America’s Blood Centers

Chief Executive Officer: Kate Fry
 Chief Medical Officer: Rita Reik
 Editor: Mack Benton
 Subscriptions Manager: Leslie Maundy
Annual Subscription Rate: \$390

Send subscription queries to
memberservices@americasblood.org
 America’s Blood Centers
 1717 K St. NW, Suite 900, Washington, DC 20006
 Phone: (202) 393-5725
 Send news tips to newsletter@americasblood.org.



America's Blood Centers®
It's About *Life.*

INSIDE ABC

The programs and services described in the Inside ABC section are available to ABC member blood centers and their staff only, unless otherwise specified.

ABC Launches Meetings Survey

America's Blood Centers (ABC) recently distributed a [survey](#) evaluating all of its in-person meetings and workshops. We encourage participation from all individuals. Your feedback is considered an important part of the evaluation process and will be used to design meeting programs that best serve the needs of attendees. All responses are valuable whether you a member or non-member of ABC, regularly attend ABC meetings and/or workshops, or have not yet had the opportunity do so. Please submit your responses to the survey by Wednesday, August 31st. Contact [us](#) with any questions.

(Source: MCN 22-071, 8/10/22)

Elks Lodges Partner with ABC to Host Blood Drives throughout August

ABC and Elks Lodges recently announced a collaboration as part of ABC's national partnership with the Student Leadership Council (SLC), a Department of Veteran Affairs Student Volunteer program. Through this collaboration, Elks Lodges agreed to host blood drives during the month of August as "SLC students have chosen blood donation as part of their national volunteer initiative." ABC is assisting them to host blood drives in their local community to compliment the VA's national blood drive initiative. A blog post on the partnership written by ABC Chief Executive Officer Kate Fry, MBA, CAE was published on the Elks National Veterans Service Commission [Blog](#) on August 8th. Please contact ABC Director of Strategic Communications and National Partnerships [Jeff Gohringer](#) with any questions.

(Source: Elks National Veterans Service Commission [Blog](#), 8/8/22)

ABC Partners to Attempt World Record Blood Drive

America's Blood Centers (ABC) recently [announced](#) a partnership with [Who is Hussain](#), a global not-for-profit community service organization that is partnering with blood centers internationally and across the U.S. in an attempt to break the world record for blood donations from a single group in a 24-hour period. This event serves the dual purpose of increasing blood donations and blood donation awareness, while educating individuals about the need for blood donation worldwide from new and diverse donors. The current world record stands at 33,000 blood donations worldwide. Their global goal is to generate more than 50,000 donations on August 27, 2022 – a day they are calling #GlobalBloodHeroes Day. Some ABC member centers are already working directly with Who is Hussain on this effort as they attempt to connect prospective donors to local, participating blood centers. We are inviting all interested members to join this effort. Note that you do not need to be listed on their website to take part. Each participating blood center should confirm their donation figures via email to Official World Record, a verification body recognized by the Council of Notariats of the European Union. More information about the confirmation process is available to ABC members in MCN 22-069. Please contact ABC Director of Strategic Communications and National Partnerships [Jeff Gohringer](#) with any questions.

(Source: MCN 22-069, 8/9/22) 💧



MEMBER NEWS



LifeServe Blood Center held a groundbreaking this week for a new facility in Johnston, Iowa. The blood center's new headquarters will include "a donor center, brand-new blood drive and blood center support spaces, a 24/7 lab for blood processing, and outdoor and indoor spaces aimed at encouraging meaningful interaction between LifeServe staff, volunteers, and donors" according to a [report](#) from WHO NBC-13. Construction on the facility is expected to be complete by 2024. "So, Johnston and this particular location at the corner of Merle Hay and Johnston is the perfect fit for us," said LifeServe President and Chief Executive Officer Stacy Sime to the news organization. "Because we wanted a spot that still kept

our community presence, and this really allows us to do it."

(Source: WHO NBC-13, [LifeServe Blood Center breaks ground on new Johnston facility](#), 8/23/22)

Although there has been no evidence of transfusion-transmitted SARS-CoV-2 resulting in COVID-19 and the U.S. blood supply is extraordinarily safe, a [study](#) published in *The Journal of Clinical Investigation* that included researchers at ABC members **Vitalant**, **New York Blood Center**, and **Bloodworks Northwest** sought to assess to what degree SARS-CoV-2 could find its way into the blood supply from pre-symptomatic donors, and what if any impact it could have on patient care. The first-of-its-kind study, funded by the National Heart, Lung and Blood Institute, the National Institute of Allergies and Infectious Diseases, and Grifols Diagnostic Solutions, Inc. also included researchers from the American Red Cross. It was conducted through the REDS-IV-P program and used blood plasma samples from 2,250 blood donors throughout the U.S. who reported COVID-19 symptoms or diagnosis after donating blood. SARS-CoV-2 RNA was detected in up to 15 percent of the samples that were acquired before widespread vaccination. However, susceptible cell lines or mice exposed to the samples remained virus free. These findings suggest blood plasma collected by blood centers from donors with pre-symptomatic COVID-19 continues to be highly unlikely to transmit SARS CoV-2 infection.

(Source: Vitalant Announcement, 8/25/22)

Contributed by Nick Gehrig, Senior Director of Communications at Vitalant

Citation: Saá, P., Fink, R.V., Bakkour, S. *et al.* [Frequent detection but lack of infectivity of SARS-CoV-2 RNA in pre-symptomatic, infected blood donor plasma](#). *The Journal of Clinical Investigation*. 2022. 💧

PEOPLE



Susan Rossmann, MD, PhD will retire as chief medical officer (CMO) at Gulf Coast Regional Blood Center by the end of 2022. She has been a member of the blood center's executive staff since September 2001 when she joined as medical director. Dr. Rossmann assumed the role of CMO in 2004. During her 21 year career at the blood center, she has been a vital part of the blood community at both the local and national levels including serving as the primary non-voting industry representative for the U.S. Food and Drug Administration's Center for Biologics Evaluation and Research Blood Products Advisory Committee (BPAC), president of America's Blood Centers (ABC), chair of ABC's Scientific, Medical, and Technical (SMT) Committee, and a member of the ABC Working Group for Donor Education and Communication, ABC liaison

(continued on page 6)

PEOPLE (continued from page 5)

to the College of American Pathologists' Transfusion Medicine Resource Committee, and chair of the Association for the Advancement of Blood & Biotherapies (AABB) Donor History Questionnaire Task Force. Additionally, Dr. Rossmann has also served as a faculty member at Baylor College and medical director of the Blood Bank and Microbiology Laboratory at Texas Children's Hospital. According to her bio, she completed "her undergraduate studies at Mount Holyoke College and received an MA and PhD in anthropology from the University of Michigan. In 1989, she received her MD from Baylor College of Medicine, where she also completed her residency in anatomic and clinical pathology. She is board certified in both anatomic and clinical pathology and certified in blood banking/transfusion medicine by the American Board of Pathology."

(Source: Gulf Coast Regional Blood Center Announcement, 8/26/22)

Elizabeth Hartwell, MD has been named CMO of Gulf Coast Regional Blood Center effective September 1st. She has previously served as the associate vice president of Medical Services at the blood center and is an adjunct associate professor at Baylor College of Medicine. According to a blood center announcement, Dr. Hartwell has also held "assistant and associate professorships at The University of Texas Health Science Center at Houston [in addition to] positions as associate chief of Clinical Pathology and medical director of the blood donor center at Baylor St. Luke's Medical Center, medical director at Gulf Coast Regional Blood Center, and chief of Clinical Pathology and medical director of the Transfusion Service at Memorial Hermann Hospital in the Texas Medical Center. Through these positions, she gained invaluable experience working in complex hospital settings as well as in a large community blood center. She earned dual undergraduate degrees in Anthropology and Biology at New Mexico State University in Las Cruces, N.M., and then completed both Medical Technology and SBB training programs. She received her medical degree from the University of Texas Medical School in Houston, where she subsequently completed a residency in Clinical Pathology, and is board certified in both Clinical Pathology and Blood Banking/Transfusion Medicine. She is the author of numerous peer-reviewed publications and several book chapters and has served as the Primary Investigator for various research studies."

(Source: Gulf Coast Regional Blood Center Announcement, 8/26/22)

Benjamin Prijatel, MBA has been named president and chief executive officer (CEO) of Sheppard Community Blood Center (Augusta, Ga.). He will begin in this role on October 29th, succeeding Kevin Belanger, DHA, MS, MT(ASCP)SBB who will retire on November 8th. According to a blood center news release, Mr. Prijatel brings "experience and expertise in blood operations" and has "overseen many aspects of blood operations including donor recruitment, marketing, collections, training, manufacturing, and hospital services" throughout his career. He currently serves as the executive director of Blood Operations at LifeShare Blood Center (Shreveport, La.). "We are blessed to welcome such a capable individual to the Sheppard team who will build upon a solid foundation and take the blood center into a new era of innovation and growth" added Dr. Belanger in the news release.



(Source: Sheppard Community Blood Center News Release, 8/24/22)

(continued on page 7)

ABC Calendar of Events

ABC offers a variety of meetings, workshops and virtual opportunities for education and networking as well as participation in ABC business. The [calendar of events](#) includes annual and summer meetings, board meetings, workshops, and webinars, and details will be updated as confirmed. We look forward to your support and participation!

PEOPLE (continued from page 6)

Vitalant Research Institute Director Emeritus and Vice President **Michael Busch, MD, PhD** recently became president of the International Society of Blood Transfusion (ISBT). His term will run through 2024. In an [interview](#) with *Transfusion Today*, Dr. Busch stated that his goals as president, which will be refined to align with the ISBT Strategic Plan, include “formulating ‘lessons learned’ from the COVID-19 pandemic including the broad impact of SARS-CoV-2 on blood bank organizations and the science and practice of transfusion medicine throughout the world, and ‘toolkits’ to be prepared for future emerging infectious disease outbreaks/pandemics; [and] advancing the application of linked national and international registries, linked donor-recipient databases and repositories, to support analyses of blood collection/processing/testing, transfusion utilization, efficacy, and safety and the vision of ‘Precision Transfusion Medicine.’”

(Source: Vitalant Announcement, 8/24/22) 💧

GLOBAL NEWS

BioMarin Pharmaceutical Inc. has been [granted](#) “conditional marketing authorization” by the European Commission (EC) for a gene therapy to treat hemophilia A in adults “without a history of Factor VIII inhibitors and without detectable antibodies to adeno-associated virus serotype 5 (AAV5).” According to the news release, “[t]he EC also endorsed European Medicines Agency’s (EMA) recommendation for [the gene therapy] to maintain orphan drug designation, thereby granting a 10-year period of market exclusivity. The EMA recommendation noted that, even in light of existing treatments, [the gene therapy] may potentially offer a significant benefit to those affected with severe [h]emophilia A. The one-time infusion is the first approved gene therapy for hemophilia A and works by delivering a functional gene that is designed to enable the body to produce Factor VIII on its own without the need for continued hemophilia prophylaxis, thus relieving patients of their treatment burden relative to currently available therapies. People with hemophilia A have a mutation in the gene responsible for producing Factor VIII, a protein necessary for blood clotting.”

(Source: BioMarin Pharmaceutical, Inc. [News Release](#), 8/24/22) 💧

COMPANY NEWS

Valneva SE has [begun](#) the “rolling submission of the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval of the [c]ompany’s single-shot [investigational] chikungunya [vaccine] in persons aged 18 years and above.” According to a company news release, “Valneva is currently targeting the end of 2022 for completion of the BLA submission... This BLA submission follows final pivotal Phase 3 data [reported](#) in March 2022.”

(Source: Valneva SE [News Release](#), 8/18/22)

QuidelOrtho Corporation [announced](#) that it has joined the Alliance for a Strong Blood Supply. The alliance was formed by the Association for the Advancement of Blood & Biotherapies (AABB) and includes both America’s Blood Centers (ABC) and ADRP, an International division of ABC, as members of the coalition. According to QuidelOrtho’s news release, the Alliance features 25 organizations “collectively represent[ing] the nation’s hospitals and blood collectors, as well as more than 200,000 physicians who routinely provide blood to patients in need” and are committed “to ensuring sufficient blood is available for all patients during the pandemic and beyond.” Douglas Bryant, chair and chief executive officer (CEO) of QuidelOrtho, added in the news release, “[w]e are honored to join the Alliance and work with its member

(continued on page 8)

COMPANY NEWS (continued from page 7)

organizations to identify actionable, near-term solutions to our nation's increasingly dangerous blood supply shortage. As a global leader in performing blood typing and blood screening, we acutely understand the critical need for safe and abundant blood to meet the needs of our hospital and laboratory partners and the patients we ultimately serve.”

(Source: QuidelOrtho Corporation [News Release](#), 8/15/22)

Moderna, Inc. [announced](#) this week that it has completed a submission requesting emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its “BA.4/BA.5 Omicron-targeting bivalent COVID-19 booster vaccine, mRNA-1273.222. The application is for a 50 µg booster dose for adults 18 years of age and older, and is based on preclinical data as well as clinical trial data available for the company's BA.1 Omicron-targeting bivalent booster candidate...mRNA-1273.222 targets both the original strain of SARS-CoV-2 as well as the BA.4/BA.5 subvariants of the Omicron strain.”

(Source: Moderna, Inc. [News Release](#), 8/23/22)

Pfizer Inc. and **BioNTech SE** have finished their [submission](#) requesting EUA for a booster dose of the companies' “Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine for individuals 12 years of age and older.” According to a news release, the “application follows guidance from the FDA to include clinical data from the companies' bivalent Omicron BA.1-adapted vaccine and pre-clinical and manufacturing data from the companies' bivalent Omicron BA.4/BA.5-adapted vaccine to address the continued evolution of SARS-CoV-2...The bivalent vaccine contains mRNA encoding the original SARS-CoV-2 spike protein, which is present in the original Pfizer-BioNTech COVID-19 Vaccine, together with mRNA encoding the spike protein of the Omicron BA.4/BA.5 variant. Pre-clinical data showed a booster dose of Pfizer and BioNTech's Omicron BA.4/BA.5-adapted bivalent vaccine generated a strong neutralizing antibody response against Omicron BA.1, BA.2 and BA.4/BA.5 variants, as well as the original wild-type strain. A clinical study investigating the safety, tolerability, and immunogenicity of the Omicron BA.4/BA.5-adapted bivalent vaccine in individuals 12 years of age and older is expected to start this month.”

(Source: Pfizer Inc. and BioNTech SE [News Release](#), 8/22/22) 💧

CALENDAR

Note to subscribers: Submissions for a free listing in this calendar (published weekly) are welcome. Send information to newsletter@americasblood.org. (For a more detailed announcement in the weekly “Meetings” section of the newsletter, please include program information.)

2022

Aug. 29-30. **NHLBI of the National Institutes of Health (NIH) and the Office of the of the Assistant Secretary of Health (OASH) of the Department of Health and Human Services (HHS) 2022 State of the Science in Transfusion Medicine Workshop (Virtual)**. Registration is [open](#). More information available [here](#).

Sept. 19-22. **American Association of Tissue Banks Annual Meeting, San Antonio, Texas**. More information available [here](#).

Sept. 20-22. **2022 Center for Biologics Evaluation and Research (CBER) Science Symposium (Virtual)**. Registration is [open](#). More information available [here](#).

Sept. 21-22. **28th IPFA/ Paul-Ehrlich-Institut[e] (PEI) International Workshop on Surveillance and Screening of Blood-borne Pathogens, Porto, Portugal**. Registration is [open](#). More information available [here](#).

(continued on page 9)

CALENDAR (continued from page 8)

Sept. 28-29. **2022 ADRP Master Class (Virtual)**. Registration is [open](#).

Sept. 28-29. **BEST Meeting LXIV, Cocoa Beach, Fla.** More information available [here](#).

Oct. 1-4. **Association for the Advancement of Blood & Biotherapies Annual Meeting, Orlando, Fla.** Registration is [open](#). More information available [here](#).

Nov. 15-16. **The Biomedical Advanced Research and Development Authority (BARDA) Industry Day (Virtual)**. More details available [here](#).

2023

Mar. 6-8. **ABC Annual Meeting, Washington, D.C.** More information coming soon.

May 9-11. **2023 ADRP Conference, Charlotte, N.C.** More information coming soon. 💧

Upcoming ABC Webinars – Don't Miss Out!

- **ABC HIPAA & Privacy in Blood Banking Webinar** – September 13 from 3-4 PM EDT. More information coming soon.
- **ABC Cybersecurity Threats & Mitigation for Blood Centers Webinar** – September 20 from 3-4 PM EDT. More information coming soon.

EQUIPMENT AVAILABLE

For Sale. New and Unused CompoMat G5 Units. The Blood Bank of Alaska has three new and unused CompoMat G5 Units for sale. These units have not been validated or used. If interested, please contact Bryan Baynard at bbaynard@bbak.org or (907) 222-5664.

CLASSIFIED ADVERTISING

Classified advertisements, including notices of positions available and wanted, are published free of charge for a maximum of three weeks per position per calendar year for ABC institutional members. There are charges for non-members: \$139 per placement for *ABC Newsletter* subscribers and \$279 for non-subscribers. A six (6) percent processing fee will be applied to all credit card payments. Notices ordinarily are limited to 150 words. To place an ad, e-mail: newsletter@americasblood.org

POSITIONS

Director of Hospital Services and Manufacturing. Blood Bank of Alaska (BBAK) is seeking a director to oversee our Hospital Services and Manufacturing Department in Anchorage, AK. This position is responsible for ensuring our manufacturing and distribution areas are operating in compliance with applicable government regulations, and accrediting agency standards. Also ensuring there is a dedicated focus on the production and distribution of quality products while providing the highest level of customer service. The Director will participate as a member of the blood bank's management team in planning, program formulation, and decision making for the functions and technical support of the

manufacturing and distribution of blood products. The incumbent for this role must possess excellent conceptual, communication and analytical skills. Must understand general workflow processes and equipment used in a medical facility. The right candidate will have a bachelor's degree in a relevant field (required) and five years of supervisory experience in a highly regulated, fast-paced, and compliance-driven environment (preferred). We are committed to providing our employees with the support they need. At BBAK we offer an attractive benefit package that includes: Medical, Dental, Vision, Life

(continued on page 10)

POSITIONS (continued from page 9)

Insurance, Health Savings Plan, Paid Time Off, 401 K with matching and Short Term & Long-Term Disability coverage. If you meet the above qualifications, please apply by sending your resume to: mcannon@bbak.org. For more information about the Blood Bank of Alaska, please visit our website at <https://www.bloodbankofalaska.org>.

Medical Director (Gulf Coast Regional Blood Center).

Reporting to the Chief Medical Officer, this individual will assist in providing oversight of operational and implementation expertise across multiple areas of a large community blood center. Areas of responsibility include medical oversight of selection and care of donors, collection, processing, and testing of blood, and disease notification. In addition, this individual will provide guidance for The Blood Center's transfusion service activities and cellular therapy programs, as well as serving as a liaison with medical staff in the community to address transfusion concerns and assure the appropriate utilization of blood products. Requirements: Doctor of Medicine or Doctor of Osteopathy degree from an accredited university with at least four years of combined education and experience in blood banking/transfusion medicine or related field. Board certified or board-eligible in Pathology, Hematology, or related field. Specialty training and/or certification in Blood Banking, Hematology, or a similar related field is highly desirable. Eligible for medical license in the state of Texas. Applicants with additional medical or management experience in apheresis related to cellular therapy and transplant are strongly encouraged to apply. Click [here](#) to apply.

Divisional Director. The Blood Connection, formerly Carolina-Georgia Blood Center, is expanding our operations into Augusta, Georgia! We are one of the fastest growing blood centers in the country and we are looking to hire a Divisional Director who will be responsible for our day-to-day operations and help direct our expansion of services into this new territory. The ideal candidate is a results-focused self-starter with progressive leadership experience and the drive to help fulfill the needs of our community partners. We offer a generous benefits package including a great 401k match, tuition reimbursement, yearly increases, company bonus, cell phone stipend, and 30 days PTO. Join our team and help make an impact in your community today! Click [here](#) to apply.

Donor Testing Laboratory Director. LifeSouth Community Blood Centers and The National Blood Testing Cooperative (NBTC) are currently seeking a skilled individual for the Donor Testing Laboratory Director position in the NBTC owned Donor Testing Laboratory in **Stone Mountain, GA**. This position is responsible for the strategic planning, development, organization, coordination, management, and daily oversight of all activities associated with a blood testing laboratory. This position will also ensure the laboratory performs in accordance with all regulatory requirements and will possess the oversight and responsibility of all standard operating procedures (SOPs) within the lab. Must have bachelor's degree in: chemical, physical, biological, clinical laboratory science, or medical technology. Scientific and technical knowledge from current sources, such as the AABB Standards and relevant guidances related to FDA, CLIA, and CMS, both state and federal. Minimum of four years of management/supervisory experience required; Equivalent combination of demonstrated work experience and education may be considered. Starting salary range is \$135,000 - \$150,000 annually. Click [here](#) to apply. 💧